{
  "main_header": {
    "sid": 1003386,
    "name": "Cohance Life",
    "stock_name": "Cohance Life",
    "full_name": "Cohance Lifesciences Ltd",
    "name_url": "stocks-analysis/cohance-life",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "464.25",
    "chg": 17.15,
    "chgp": "3.84%",
    "dir": 1,
    "prev_price": "447.10",
    "mcapval": "17,760.68 Cr",
    "mcap": "Small Cap",
    "scripcode": 543064,
    "symbol": "COHANCE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE03QK01018",
    "curr_date": "Aug 11",
    "curr_time": "",
    "bse_nse_vol": "24.79 lacs",
    "exc_status": "Active",
    "traded_date": "Aug 11, 2026",
    "traded_date_str": "2026 08 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/cohance-life-1003386-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Cohance Lifesciences Ltd Surges 7.57% to Day's High of Rs 458.8 — Outperforms Sector by 4.75 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-hits-intraday-high-with-757-surge-on-19-may-2026-3998541",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_priceRelatedfactors_3998541.png",
        "date": "2026-05-19 09:32:00",
        "description": "The Sensex edged up 0.51% on 19 May 2026, but Cohance Lifesciences Ltd outpaced the broader market with a robust 7.57% gain, marking a 4.75 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers. This sharp intraday advance rewrites the short-term narrative for the small-cap stock, raising questions about whether this is a genuine recovery or a technical bounce within a mixed trend."
      },
      {
        "title": "Are Cohance Lifesciences Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-cohance-lifesciences-ltd-latest-results-good-or-bad-3989988",
        "imagepath": "",
        "date": "2026-05-13 19:21:48",
        "description": "Cohance Lifesciences Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported a consolidated net profit of ₹19.55 crores, reflecting a substantial year-on-year decline of 83.77%. Net sales also experienced a notable contraction, decreasing by 26.33% year-on-year to ₹619.12 crores. This marks the fourth consecutive quarter of negative year-on-year growth, indicating a troubling trend in revenue generation.\n\nOperating margins have compressed significantly, falling to 15.94% from 27.27% in the previous year, which suggests difficulties in cost management and pricing power. The profit before tax showed an 87.62% decline year-on-year, further exacerbated by an unusually high tax rate of 58.26%, which is well above the company's historical average. \n\nOn a sequential basis, there was a marginal improvement in sales, which rose by 13.69% from the previous quarter, a..."
      }
    ],
    "total": 15,
    "sid": "1003386",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/cohance-lifesciences-1003386"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "06-Aug-2026",
      "details": "Newspaper Publication",
      "source": "BSE"
    },
    {
      "caption": "Completion Of USFDA Inspection",
      "datetime": "05-Aug-2026",
      "details": "Completion of USFDA Inspection",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "05-Aug-2026",
      "details": "Con Call audio link",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cohance Lifesciences Ltd has declared <strong>100%</strong> dividend, ex-date: 09 Sep 22",
          "dt": "2022-09-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Cohance Lifesciences Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 25 Sep 20",
          "dt": "2020-09-25",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Cohance Lifesciences Ltd Surges 7.57% to Day's High of Rs 458.8 — Outperforms Sector by 4.75 Percentage Points

2026-05-19 09:32:00

The Sensex edged up 0.51% on 19 May 2026, but Cohance Lifesciences Ltd outpaced the broader market with a robust 7.57% gain, marking a 4.75 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers. This sharp intraday advance rewrites the short-term narrative for the small-cap stock, raising questions about whether this is a genuine recovery or a technical bounce within a mixed trend.

Read More

Are Cohance Lifesciences Ltd latest results good or bad?

2026-05-13 19:21:48

Cohance Lifesciences Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported a consolidated net profit of ₹19.55 crores, reflecting a substantial year-on-year decline of 83.77%. Net sales also experienced a notable contraction, decreasing by 26.33% year-on-year to ₹619.12 crores. This marks the fourth consecutive quarter of negative year-on-year growth, indicating a troubling trend in revenue generation. Operating margins have compressed significantly, falling to 15.94% from 27.27% in the previous year, which suggests difficulties in cost management and pricing power. The profit before tax showed an 87.62% decline year-on-year, further exacerbated by an unusually high tax rate of 58.26%, which is well above the company's historical average. On a sequential basis, there was a marginal improvement in sales, which rose by 13.69% from the previous quarter, a...

Read More

View All News